Search

everythinglearnresearchcommunity

for

Search:↓

Diagnosing alopecia areata is challenging and requires careful examination and various tests to distinguish it from other hair loss types.

Topical latanoprost and bimatoprost eye solutions don't help eyelash growth in people with alopecia areata.

Tofacitinib helped some young children with severe hair loss grow their hair back without bad side effects.

Bimatoprost helped eyelash growth in nearly half of the patients with a type of eyelash hair loss.

Certain scalp patterns can indicate the severity and activity of hair loss in Turkish alopecia patients.

A woman's eyelash regrowth was successful using tofacitinib solution for alopecia areata.

Non-immune factors play a significant role in alopecia areata.

Chemotherapy may cause recurring hair loss due to an autoimmune response.

Both dermatologists and patients in Japan agree that treatment success for alopecia areata is having 20% or less scalp hair loss.

Upadacitinib may effectively treat alopecia areata without side effects.

Some multiple sclerosis treatments may trigger hair loss conditions like alopecia areata.

Combining corticosteroids and non-ablative fractional laser therapy may effectively treat extensive alopecia areata.

Alopecia areata is relatively common in children, has a variable course, and shows different responses to treatment; thyroid testing is recommended for those affected.

Topical latanoprost and bimatoprost ophthalmic solutions don't help eyelash growth in patients with alopecia areata.

Half of people with Alopecia Areata may see hair regrowth within a year without treatment, but recovery is unpredictable.

Guidelines suggest various treatments for alopecia areata, but leaving it untreated is also an option as 80% cases may recover on their own.

Some treatments can help with a hair loss condition called alopecia areata, but none ensure lasting results; choices depend on the person, with JAK inhibitors showing promise for severe cases.

A new type of rapid hair loss called ADTA usually gets better on its own within 6 months.

Drugs targeting the JAK/STAT pathway can improve atopic dermatitis but vary in effectiveness for vitiligo and alopecia areata, with generally mild safety concerns.

3% topical minoxidil effectively treats extensive alopecia areata with few side effects.

New treatments for severe hair loss often fail, but some patients see hair regrowth with specific therapies, and treatment should be tailored to the individual's situation.

Alopecia Areata has no guaranteed treatment for hair regrowth, but options like corticosteroids and minoxidil are used, with future research focusing on genetic and immune therapies.

Despite progress in treatment, the exact cause of Alopecia areata is still unknown.

Combining diphenylcyclopropenone with anthralin is more effective for hair regrowth in alopecia areata than using diphenylcyclopropenone alone, but may cause more side effects.

Oral JAK inhibitors are effective and safe for treating alopecia areata but may need ongoing use to keep results.

Tofacitinib shows promise for treating severe hair loss in adults and teens, with many experiencing regrowth, but hair loss returns when treatment stops.

Monochromatic light devices, especially the 308-nm excimer laser, are promising for treating alopecia areata but more research is needed.

Female donor to male recipient sex mismatch and positive ACA-IgG are key risk factors for vitiligo and alopecia areata in chronic GvHD patients.

Oral tofacitinib may effectively treat hair loss in children with alopecia areata.

A man with severe hair loss saw hair and nail improvement after 10 months on tofacitinib without side effects.